Literature DB >> 23518784

Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: A case report.

Dante Durand1, Leticia L Delgado1, Dhizarah Matus de la Parra-Pellot1, Diana Nichols-Vinueza2.   

Abstract

BACKGROUND: Synthetic cannabinoid (SC) or "spice" refers to a variety of herbal/chemical mixtures, which mimic the effects of marijuana. They are generally marked as "herbal incense" and best known by the brand names of "K2," "spice," "aroma," "Mr. Nice Guy" and "dream." Little data are available on the psychopathological and physical effects of SC. CASE DESCRIPTION: We reported on a 23-year-old man without prior psychiatric history who developed acute psychosis and severe rhabdomyolysis (creatine phosphokinase [CPK]: 44,300 UI/L) associated with "Mr. Nice Guy" consumption. To our knowledge, this is the first case report of severe rhabdomyolysis associated with SC use in the U.S.
CONCLUSIONS: Physicians should be aware of the possibility of new-onset psychotic symptoms and rhabdomyolysis in patients that use SC.

Entities:  

Keywords:  Creatine Phosphokinase (CPK); Psychosis; Rhabdomyolysis; Spice; Synthetic Cannabinoids (SC)

Mesh:

Substances:

Year:  2015        PMID: 23518784     DOI: 10.3371/CSRP.DUDE.031513

Source DB:  PubMed          Journal:  Clin Schizophr Relat Psychoses        ISSN: 1935-1232


  15 in total

Review 1.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 2.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

3.  McArdle disease: a "pediatric" disorder presenting in an adult with acute kidney injury.

Authors:  Xixi Zhao; Angela Li; Madhu Soni; Michael J Muriello; Carolyn H Jones; William L Whittier
Journal:  CEN Case Rep       Date:  2017-06-28

Review 4.  Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.

Authors:  Vikas Khullar; Ankur Jain; Maryam Sattari
Journal:  J Gen Intern Med       Date:  2014-02-20       Impact factor: 5.128

5.  Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication.

Authors:  Ahmet Kırgız; Havva Kaldırım
Journal:  Int Ophthalmol       Date:  2017-12-23       Impact factor: 2.031

Review 6.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

Review 7.  Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.

Authors:  Ziva D Cooper
Journal:  Curr Psychiatry Rep       Date:  2016-05       Impact factor: 5.285

Review 8.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

9.  Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high.

Authors:  Dolkar Sherpa; Bishow M Paudel; Bishnu H Subedi; Robert Dobbin Chow
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-09-01

10.  Rhabdomyolysis and Acute Kidney Injury Requiring Dialysis as a Result of Concomitant Use of Atypical Neuroleptics and Synthetic Cannabinoids.

Authors:  Aiyu Zhao; Maybel Tan; Aung Maung; Moro Salifu; Mary Mallappallil
Journal:  Case Rep Nephrol       Date:  2015-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.